In the hardly shocking department it looks as though another Sanofi (NYSE: SNY) diabetes partnership is on the fritz. This time it’s Zealand Pharma who’s not a happy camper. Zealand partnered with Sanofi on Soliqua and not shocking sales have been less than impressive. So, Zealand has decided for their next drug they will go it alone.
Now we don’t want to say we told you so. No, we don’t want to say that signing a diabetes partnership with Sanofi is one of the dumbest moves a company can make. Or that every diabetes partnership with . . .
This content is restricted to subscribers. Please subscribe.
Already have an account? Please login.